Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents

被引：0
|
作者：
M N Saha
Y Chen
M-H Chen
G Chen
H Chang
机构：
[1] Toronto General Research Institute,Division of Molecular and Cellular Biology
[2] University of Toronto,Department of Laboratory Medicine & Pathobiology
[3] The First Affiliated Hospital of Nanchang University,Department of Hematology
[4] University Health Network,Department of Laboratory Hematology and Medical Oncology
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
myeloma; MIRA; p53; apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2224 / 2231
页数：7
相关论文
共 50 条
  • [31] In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
    Negri, Joseph M.
    McMillin, Douglas W.
    Delmore, Jake
    Mitsiades, Nicholas
    Hayden, Patrick
    Klippel, Steffen
    Hideshima, Teru
    Chauhan, Dharminder
    Munshi, Nikhil C.
    Buser, Carolyn A.
    Pollard, John
    Richardson, Paul G.
    Anderson, Kenneth C.
    Mitsiades, Constantine S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (05) : 672 - 676
  • [32] Thalidomide metabolism and its anti-myeloma efficacy in vivo.
    Yaccoby, S
    Johnson, CL
    Mahaffey, SC
    Barlogie, B
    Epstein, J
    [J]. BLOOD, 1999, 94 (10) : 317A - 317A
  • [33] Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease
    Terpos, Evangelos
    Christoulas, Dimitrios
    Kastritis, Efstathios
    Migkou, Magda
    Gavriatopoulou, Maria
    Dimopoulos, Meletios-Athanassios
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S30 - S32
  • [34] Discovery of novel FGF trap small molecules endowed with anti-myeloma activity
    Taranto, Sara
    Castelli, Riccardo
    Marseglia, Giuseppe
    Scalvini, Laura
    Vacondio, Federica
    Gianoncelli, Alessandra
    Ribaudo, Giovanni
    Faletti, Jessica
    Gazzaroli, Giorgia
    Rocca, Edoardo
    Ronca, Roberto
    Rusnati, Marco
    Sacco, Antonio
    Roccaro, Aldo Maria
    Presta, Marco
    Mor, Marco
    Giacomini, Arianna
    Rivara, Silvia
    [J]. PHARMACOLOGICAL RESEARCH, 2024, 206
  • [35] Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo
    Yarde, Danielle N.
    Nace, Rebecca A.
    Russell, Stephen J.
    [J]. EXPERIMENTAL HEMATOLOGY, 2013, 41 (12) : 1038 - 1049
  • [36] Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide
    Zhu, Yuan Xiao
    Braggio, Esteban
    Shi, Chang-Xin
    Schmidt, Jessica
    Bruins, Laura
    Schuster, Steven R.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Bjorklund, Chad C.
    Orlowski, Robert Z.
    Stewart, A. Keith
    [J]. BLOOD, 2011, 118 (21) : 61 - 62
  • [37] The anti-myeloma effect of bortezomib is associated with osteoblastic activity.
    Zangari, M
    Najarian, KB
    Esseltine, DL
    Lee, CK
    Barlogie, B
    Elice, F
    Burns, MJ
    Yaccoby, S
    Richardson, P
    Sonneveld, P
    [J]. BLOOD, 2005, 106 (11) : 152A - 153A
  • [38] Anti-myeloma effects induced by myeloma idiotype pulsed dendritic cells in vitro.
    Zhang, M
    Yin, XR
    Luo, YY
    Lin, X
    He, PC
    Wang, MC
    Li, J
    Liu, YL
    Guo, GL
    Cai, RB
    Qiu, L
    [J]. BLOOD, 2005, 106 (11) : 366B - 366B
  • [39] The ellipticine derivative NSC 338258 has anti-myeloma activity
    Tian, EM
    Stephens, O
    Holbeck, S
    Barlogie, B
    Shaughnessy, J
    [J]. BLOOD, 2005, 106 (11) : 944A - 944A
  • [40] Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1
    Chauhan, Dharminder
    Bandi, Madhavi
    Singh, Ajita V.
    Podar, Klaus
    Richardson, Paul G.
    Munshi, Nikhil C.
    Viktorsson, Kristina
    Lewensohn, Rolf
    Spira, Jack
    Anderson, Kenneth C.
    [J]. BLOOD, 2010, 116 (21) : 767 - 767
12345